NCT Number: NCT02184936
Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke
Treatment of acute ischemic stroke (AIS) is aimed at salvaging viable but ischemic brain by opening the occluded artery and restoring anterograde perfusion as quickly as possible. Time saved while making critical decisions correctly is vital in AIS management. Conventional angiography is invasive, resource intensive and not feasible as a fast diagnostic tool. Perfusion CT and MRI are both susceptible to patient motion, need trained personnel to process and take at least 10-30 min to acquire and interpret. The investigators have developed a new imaging tool, multi-phase CT Angiography (CTA), which generates multiple time resolved images of backfilling arteries beyond a blocked artery filled by collaterals.
Investigators seek to determine: i) if patients with AIS will have a differential clinical response to early recanalization based on collateral status assessed on multi-phase CTA, ii) if the extent to which collateral assessment on multi-phase CTA resembles perfusion CT in predicting which patients will have good clinical outcome with early recanalization, iii) Identify determinants of variability in native collateral status in patients with acute ischemic stroke.
Investigators hypothesize that patients with good and intermediate collaterals on multi-phase CTA achieve good clinical outcome with early recanalization (within 4 hours of baseline imaging); patients with poor collaterals do not do well even with early recanalization.
Prove-IT is a prospective multi-center hospital-based cohort study of 500 consecutive patients with acute ischemic stroke presenting within 12 hours of stroke symptom onset with evidence of intracranial occlusion on routine CTA over 3 years. Calgary and seven other comprehensive stroke centers will recruit patients into this study. Primary outcome is defined as a National Institute of Health Stroke Scale (NIHSS) score of 0 to 2 at 24 hours or an 8-point drop in NIHSS score from baseline to 24 hours. Secondary outcomes are a) 90-day modified Rankin Score (mRS) 0-2 or equal to the pre-stroke mRS; b) percent neurologic improvement comparing NIHSS at baseline to 24 hours; c) 90-day NIHSS score 0-2; d) infarct volume on 24 hour imaging and e) parenchymal intracerebral hemorrhage type 1 and 2 (ECASS II criteria) at 24 hrs.
Prove-IT looks to establish the ideal imaging selection tool for intra-arterial (IA) and thrombolysis decisions in the setting of AIS which is widely available, and can quickly and reliably detect salvageable brain.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Foothills Medical Centre, Calgary, Alberta, Canada
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient presenting to the emergency department with symptoms consistent with ischemic stroke.
- Age > 18 yrs.
- Baseline imaging including multi-phase CTA done within 12 hours of stroke symptom onset and initiated before recanalization therapy.
- Evidence of a visible and symptomatic intracranial occlusion on baseline CT-angiography (intracranial ICA, M1 MCA segment +/- intracranial ICA, proximal M2 MCA).
- Treatment with IV tPA and/or IA therapy.
Exclusion criteria
- Intracranial hemorrhage (ICH) identified on baseline CT.
- Previous moderate to large stroke in the ipsilesional hemisphere.
- Modified Rankin Scale > 2 at baseline.
- Unable to have CT-angio performed due to recent estimated creatinine clearance eCCr<60 ml/min, contrast allergy or other reasons.
- Participation in another study that results in the patient receiving an investigational drug or therapy.
- Any terminal illness (patient not expected to survive > 1 year).
Treatment and study plan
Primary outcomes
-
Major neurological improvement at 24 hours
Time frame: 24 hours post stroke onset
defined as a NIHSS score of 0 to 2 at 24 hours or an 8-point drop in NIHSS score from baseline to 24 hours.
Secondary outcomes
-
90 day clinical outcome
Time frame: 90 days
- 90-day modified Rankin Score (mRS) 0-2 or equal to the pre-stroke mRS
- Ordinal (shift) analysis across the mRS scale
-
percent neurologic improvement comparing NIHSS at baseline to 24 hours
Time frame: 24 hours
-
90-day NIHSS score 0-2
Time frame: 90 days
-
Radiological outcome
Time frame: 24 hours
infarct volume on 24 hour imaging and parenchymal intracerebral hemorrhage type 1 and 2 (ECASS II criteria) at 24 hrs
Sponsors and collaborators
Lead sponsor
Carol Kenney
Other
Registry information
Official study title
Precise and Rapid Assessment of Collaterals Using Multi-phase CTA in the Triage of Patients With Acute Ischemic Stroke for IA Therapy
Acronym: PRove-IT
Important dates
- Study start
- 2012
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jul 9, 2014
- Registry last updated
- Oct 30, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease
NCT07600996
Alzheimer Disease, Alzheimer Disease (AD)
Beijing, None Selected, China
View Trial DetailsCOAgulation Disorders in Ischaemic and Haemorrhagic Stroke
NCT05974111
Aneurysmal Subarachnoid Hemorrhage, Brain Diseases
Genk, Belgium
View Trial DetailsA Trial of Rehabilitation Paired With VNS for Motor Function in Patients With Stroke (Repair Study)
NCT06722677
Brain Diseases, Cardiovascular Diseases
Hefei, Anhui, China
View Trial DetailsSmartWatch-driven AF Detection in Stroke Patients
NCT06832579
Arrhythmias, Cardiac, Atrial Fibrillation
Bad Neustadt an der Saale, Germany
View Trial Details